Japan approves Bristol Myers Squibb’s B-cell lymphoma therapy

Bristol Myers Squibb has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for its Breyanzi (lisocabtagene maraleucel; liso-cel) to treat patients suffering from relapsed or …
( read original story …)

---